GLP-1RAs show anti-cancer benefits beyond weight loss
The observational study (COM2-0186-22), presented during the European Congress on Obesity (ECO) taking place in Malaga, Spain between 11-14 May and published in the journal eClinicalMedicine, investigated first-generation GLP-1RAs Victoza (liraglutide) and Byetta (exenatide).
The study found that GLP1-RAs had a direct effect on reducing obesity-related cancer beyond weight loss, with a 41% lower relative risk compared to bariatric surgery.
Researchers analysed electronic health record data and over a median follow-up of 7.5 years, 298 patients were diagnosed with obesity-related cancer. Of these cases, 150 were from 3,178 surgery patients (5.76 cases per 1,000 person-years) compared with 148 cases from 3,178 patients taking GLP-1RAs (5.64 cases per 1,000 person-years). This comes as bariatric surgery in weight reduction is already known to reduce cancer risk.
The most common cancer was postmenopausal breast cancer (26%), followed by colorectal cancer (16%), and cancer of the uterus (15%).
To assess the comparative effect beyond the extent of weight loss (which mediates the reduction in cancer risk following treatment), the researchers further adjusted the analysis for the percentage of maximal BMI change during follow-up.
Co-lead author Dr Yael Wolff Sagy from Clalit Health Services, Tel-Aviv, Israel, said: 'Our study found a similar incidence of obesity-related cancer among patients treated with first-generation GLP-1RAs and with bariatric surgery over an average of 8 years follow-up, despite the relative advantage of surgery in maximising weight loss. But accounting for this advantage revealed the direct effect of GLP-1RAs beyond weight loss to be 41% more effective at preventing obesity-related cancer.'
Of the 6,356 study participants, 3,884 (61.1%) were females. At baseline, the mean age was 52.3 years, and the mean BMI was 41.5kg/m².
Both obesity and diabetes are linked with an increased risk for many types of cancer, referred to as obesity-related cancer, including colorectal cancer, corpus uteri cancer, meningioma and ovarian cancer, as well as multiple myeloma.
Investigators are now calling for randomised trials and larger prospective studies to confirm the anti-cancer effects of GLP-1RAs noted in the observational study and explore the underlying mechanisms.
GLP-1RAs are also being investigated in other indications beyond obesity and type 2 diabetes, including Alzheimer's disease, addictive disorders and psychiatric disorders.
GLP-1RAs have grown massively in recent years following the release of Novo Nordisk's semaglutide, marketed as Ozempic in type 2 diabetes and Wegovy in obesity, and Eli Lilly's tirzepatide, marketed as Mounjaro in type 2 diabetes and Zepbound in obesity.
GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033. Research also predicts Novo Nordisk and Eli Lilly will dominate the market, collectively capturing 94% of the total 2030 GLP-1RA sales.
GlobalData is the parent company of Clinical Trials Arena.
"GLP-1RAs show anti-cancer benefits beyond weight loss" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Sandoz to offer generic weight-loss drugs in Canada at up to 70% discount, FT reports
(Reuters) -Swiss generic drug manufacturer Sandoz plans to launch unbranded weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents begin to expire next year, CEO Richard Saynor told the Financial Times. Sandoz is yet to finalise the pricing for its generic weight-loss and diabetes drug semaglutide, but a price cut of "60 or 70 per cent of the list price" was achievable, Saynor told the newspaper. Prices could drop further as more generic versions become available, Saynor said, noting, "If you were selling this at $40 or $50 a month, the market could be two or three times bigger in terms of the number of patients." Branded weight-loss and diabetes medications, such as Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound, are currently priced between $200 and $400 for a one-month supply, according to the FT report. Novo Nordisk's medications use semaglutide as the active ingredient, while Eli Lilly's medications use tirzepatide. Sandoz did not immediately respond to a Reuters request for comment. The move comes as demand for weight-loss and diabetes drugs has surged globally, driven by their effectiveness in managing obesity and diabetes. Last month, a top Biocon executive told Reuters that the biopharmaceutical company aims to launch generic copies of the blockbuster weight-loss drug Wegovy in Canada within the next two years. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
13 hours ago
- CNBC
Hims & Hers stock falls 10% on revenue miss
Shares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street's expectations for revenue. Here's how the company did based on average analysts' estimates compiled by LSEG: Revenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or 6 cents per share, during the same period a year earlier. For its third quarter, Hims & Hers said it expected to report revenue between $570 million to $590 million, while analysts were expecting $583 million. The company said its adjusted EBITDA for the quarter will be between the range of $60 million to $70 million. Analysts polled by StreetAccount were expecting $77.1 million. Hims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, which are cheaper, unapproved versions of the blockbuster diabetes and weight loss drugs. Compounded drugs can be mass produced when brand-name treatments are in shortage, but the U.S. Food and Drug Administration announced in February that ongoing supply issues had been resolved. Some telehealth companies, including Hims & Hers, have continued to offer the compounded medications. It's legal for patients to access personalized doses of the knockoffs in unique cases, like if they are allergic to an ingredient in a branded product, for instance. Hims & Hers has said consumers may still be able to access personalized doses through its site if clinically applicable. In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart. The drugmaker said Hims & Hers "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization. Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million last year and above the $73 million expected by StreetAccount. Hims & Hers will host its quarterly call with investors at 5 p.m. ET.
New York Post
16 hours ago
- New York Post
The future of post-weight loss skincare starts at IMAGE with these new products
New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. In the world of modern aesthetics, few developments have sparked as much excitement — and concern— as the widespread use of GLP-1 medications for rapid weight loss. These groundbreaking therapies have offered millions a renewed sense of health and well-being. Yet, for all their benefits, they often leave one visible drawback: their impact on the skin. Rapid fat loss, particularly in the face, can lead to noticeable changes in skin appearance, including volume deflation, deepening wrinkles, dryness and a loss of density. Recognizing this, IMAGE Skincare has introduced a pioneering solution: the first clinically formulated skincare product designed specifically to combat the four visible effects of GLP-1-induced weight loss on the skin. Created by board-certified plastic surgeon Dr. Marc Ronert, isn't your run-of-the-mill anti-aging product. It represents a new category of targeted skincare. Advertisement IMAGE Skincare At the heart of its innovation is the GLP-1 4D Skin Rebound Complex, a proprietary blend of active ingredients meticulously chosen to address the four primary signs of facial skin aging resulting from rapid weight loss: deflation, deep wrinkles, dehydration and density loss. Dr. Ronert's approach reflects an intersection of medical science and aesthetic care, backed by years of experience treating patients who sought solutions for the facial aging effects that often follow significant weight reduction. What makes so unique is its focus on restoring what the skin loses during accelerated fat loss. Facial deflation, a hallmark of GLP-1 therapy use, can age the appearance dramatically by hollowing the cheeks and under-eye areas. The advanced volumizing technology in helps to counteract this process, encouraging a more lifted, youthful contour. After 12 weeks of consistent, twice-daily use, instrumental grading revealed a 20% increase in facial volume, underscoring the product's efficacy in restoring fullness to areas most impacted by fat depletion. But volume is only one part of the equation. The skin's structure also suffers under the strain of rapid weight loss, often resulting in sagging and loss of elasticity. The GLP-1 4D Skin Rebound Complex targets these issues with ingredients designed to improve skin's bounce and resilience. What's more, the results speak for themselves. Clinical testing showed a 23% increase in net elasticity and a 22% improvement in firmness after 12 weeks — measurable results that translate to tighter, more supple skin. These improvements not only address the visual signs of aging but also help the skin maintain its integrity as the face adapts to a new, leaner shape. Deep wrinkles, another byproduct of reduced fat cushioning in the face, are also visibly diminished with As facial support structures weaken and the skin thins, fine lines evolve into pronounced creases. is engineered to fill and smooth these lines by encouraging collagen synthesis and enhancing moisture retention. Users experienced a 20% reduction in wrinkles over a 12-week period, with noticeable improvement often beginning as early as four weeks. This means that while the transformation unfolds gradually, early signs of success are visible quickly, reinforcing the importance of consistent use. Dehydration, though often overlooked, is a critical aspect of post-weight-loss skin care. Skin that loses volume also loses its ability to retain moisture efficiently, leading to a dull, tired complexion. combats this with deeply hydrating components that strengthen the skin barrier and improve water retention, leaving the skin plumper, more radiant and visibly revitalized. This comprehensive approach is what sets apart; rather than treating symptoms in isolation, it addresses the interconnected causes behind the accelerated aging many experience after GLP-1 usage. Why You Can Trust IMAGE Skincare IMAGE Skincare What further elevates this innovation is the credibility and care behind its creation. IMAGE Skincare, founded in 2003 by aesthetician Janna Ronert, has always prioritized products that merge clean, botanical ingredients with clinical efficacy. The collaboration between Janna and Dr. Marc Ronert brings together the precision of surgical insight and the sensitivity of professional skincare. Their shared vision has positioned IMAGE Skincare as a leader in science-driven, physician-formulated solutions that are also cruelty-free and accessible to both professionals and consumers. continues this legacy with a product that feels luxurious while performing like a professional-grade treatment. The Final Verdict IMAGE Skincare For those navigating the often-unexpected changes to their appearance following GLP-1 weight loss, offers a reassuring and effective remedy. So, you can toss away your other serum and moisturizer for the time being, as this restorative treatment, designed with a deep understanding of the unique biological changes occurring beneath the surface of the skin, is one to impress. Every application helps the face rediscover its definition, its structure and its glow. And ultimately, represents a major advancement in personalized skincare. It anticipates a need that is growing rapidly as more individuals turn to metabolic treatments for weight management, and it delivers on that need with unmatched precision and efficacy. With visible improvements in volume, elasticity, firmness and wrinkle reduction (all within just a few months!) users can expect a smoother, fuller, more youthful complexion that reflects their internal transformation — with consistent use. Backed by clinical testing and guided by medical expertise, proves that you don't have to choose between your health goals and your appearance. You can have both: resilient skin that rebounds, just like you. This article was written by Victoria Giardina, New York Post Commerce Journalist & Content Strategist, who has spent countless hours researching, testing hundreds of products and comparing the latest makeup, skincare, hair and beauty items and trends to determine what's truly worth your hard-earned cash. She evaluates formulas, textures, ingredients and more, in addition to consulting medical and industry experts. Some of Victoria's latest conquests include testing the best vitamin C serums on the market, and a rinse-and-repeat review of the best shampoos of 2025. Victoria, who received a beauty industry essentials certification from the Fashion Institute of Technology, has been creating shopping guides for the New York Post since 2021 and previously held positions at Insider Reviews and CNN Underscored.
